News
Barchart on MSN1d
1 Blue-Chip Dividend Stock That Still Has Room to Run
Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...
Zacks Investment Research on MSN9h
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...
Merck won approval from the U.S. Food and Drug Administration for a shot that protects against RSV, the most common cause of hospitalization among infants, STAT notes.
Merck’s RSV drug approval and a drug manufacturer winds down Mel Evans/AP By Elaine Chen June 10, 2025 National Biotech Reporter ...
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback